Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cortexyme, Inc. - Common Stock (NQ: CRTX )

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Jul 29, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cortexyme, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
Stocks That Hit 52-Week Lows On Thursday
  On Thursday, 108 companies set new 52-week lows. 
Via Benzinga
Cortexyme Announces Further Layoffs, Chief Medical Officer Leaves
Via Benzinga
Recap of Wednesday's Biotech Catalysts - End of The Day Summary
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
  Wednesday saw 83 companies set new 52-week lows. 
Via Benzinga
Cortexyme Corporate Name Change to Quince Therapeutics to Take Effect on August 1, 2022
From Cortexyme, Inc.
Via Business Wire
Cortexyme Successfully Completes Phase 1 Single and Multiple Ascending Dose Clinical Trial of COR588
From Cortexyme, Inc.
Via Business Wire
Cortexyme Announces Preclinical Data Demonstrating Efficacy of COR803 for the Treatment of Coronavirus Infections
From Cortexyme, Inc.
Via Business Wire
Stocks That Hit 52-Week Lows On Monday
  On Monday, 100 companies reached new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
On Friday, 61 companies hit new 52-week lows. 
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers Tempest Therapeutics (NASDAQ:TPST) stock moved upwards by 34.4% to $2.81 during Thursday's after-market session. The market value of their outstanding shares is at $29.0 million. 
Via Benzinga
Cortexyme Appoints June Bray to its Board of Directors
From Cortexyme, Inc.
Via Business Wire
69 Biggest Movers From Friday
Gainers Turning Point Therapeutics, Inc. (NASDAQ: TPTX) shares climbed 118.4% to close at $74.59 on Friday after Bristol Myers Squibb announced it will acquire Turning Point Therapeutics for $76 per... 
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
On Wednesday, 73 stocks hit new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
On Tuesday, 36 companies achieved new lows for the year. 
Via Benzinga
Cortexyme Appoints Dr. Philip Low to Its Board of Directors
From Cortexyme, Inc.
Via Business Wire
Cortexyme Successfully Completes Acquisition of Novosteo
From Cortexyme, Inc.
Via Business Wire
Cortexyme to Participate at 4th International Conference on Porphyromonas gingivalis and Related Species in Oral and Systemic Diseases
From Cortexyme, Inc.
Via Business Wire
103 Biggest Movers From Yesterday
Gainers 
Via Benzinga
77 Stocks Moving In Tuesday's Mid-Day Session
Gainers 
Via Benzinga
The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Cortexyme Announces Agreement to Acquire Novosteo
From Cortexyme, Inc.
Via Business Wire
The Daily Biotech Pulse: FDA's AdComm For Acadia's Pimavanserin, Review Issues For Spero's Tebipenem Application, Cortexyme Layoffs
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
NASDAQ:CRTX Investor Alert: Investigation over Potential Wrongdoing at Cortexyme, Inc.
San Diego, CA -- (SBWIRE) -- 04/29/2022 -- Certain directors of Cortexyme, Inc. are under investigation over potential breaches of fiduciary duties. 
Via SBWire
ROSEN, RESPECTED INVESTOR COUNSEL, Encourages Cortexyme, Inc. Investors With Losses to Inquire About Securities Class Action Investigation – CRTX
From The Rosen Law Firm, P.A.
Via Business Wire
Cortexyme Provides New GAIN Trial Data at AD/PD 2022 Demonstrating Potential Benefit of Lysine Gingipain Inhibition in Mild to Moderate Alzheimer’s Population
From Cortexyme, Inc.
Via Business Wire
Short-Squeeze Stocks: Top 10 Stocks With High Short Interest Today
Short-squeeze stocks continue to be a hot topic with retail traders and we're going over the top ones to keep an eye on for Tuesday! 
Via InvestorPlace
Cortexyme Appoints Marwan Sabbagh, MD, to its Board of Directors
From Cortexyme, Inc.
Via Business Wire
Cortexyme to Present New GAIN Trial Data at AD/PD 2022
From Cortexyme, Inc.
Via Business Wire
10 Biggest Price Target Changes For Wednesday
Telsey Advisory Group cut the price target on Stitch Fix, Inc. (NASDAQ: SFIX) from $25 to $14. Stitch Fix shares fell 24.5% to $8.31 in pre-market trading. 
Via Benzinga
Cortexyme Posts Safety Data From SAD Portion Of COR588 Trial In P.Gingivalis
Cortexyme Inc (NASDAQ: CRTX) has announced results from the single ascending dose (SAD) portion of the Phase 1 trial of COR588 for diseases related to P. gingivalis infection... 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.